Company News

2026-07-10

Launch of Phase III Osteosarcoma Clinical Trial for C019199 Tablets by Haixi Pharmaceuticals

本公司董事會（「董事會」）欣然宣佈，本公司自主研發的C019199片正式啓動針對既往至少二線治療失敗的骨肉瘤的III期臨床試驗(CTR20261818)，相關信息已獲中國國家藥品監督管理局(NMPA)藥品審評中心(CDE)藥物臨床試驗登記與資訊公示平台公示。

More

2026-07-14

HXP089 Investigational New Drug (IND) Application for the Treatment of Glioblastoma Approved by National Medical Products Administration (NMPA)

More

2026-06-09

Haixi Pharma Receives CDE Approval to Initiate Phase III Clinical Study of C019199 Tablets for the Treatment of Osteosarcoma After Failure of at Least Two Prior Lines of Therapy

Fuzhou, China—Haixi Pharma (Haixi Pharma, HKEX: 02637.HK, or the "Company") is pleased to announce that C019199 has received approval from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA)

More

2026-06-08

Haixi Pharma's HXP089 Investigational New Drug (IND) Application for the Treatment of Glioblastoma Accepted by China's National Medical Products Administration (NMPA)

Fuzhou, China—Haixi Pharma (HKEX: 02637.HK, or the "Company") is pleased to announce that the Investigational New Drug (IND) application for HXP089, discovered and developed by the Company, for the treatment of glioblastoma has been

More

2026-03-24

wAMD DRUG PROJECT HXP056 COMPLETED ENROLLMENT FOR PHASE I CLINICAL STUDY AND INITIATED PHASE 2 STUDY

The board of directors (the “Board”) of Fujian Haixi Pharmaceuticals Co., Ltd. (the “ Company”) announces that HXP056, the Company’s innovative drug project and the potentially worldwide first oral therapy for hemorrhage related retinal diseases

More

2026-03-09

Haixi Pharma Admitted to Stock Connect; Mainland Investors May Trade Its H Shares Effective March 9

According to announcements issued by the stock exchanges, effective March 9, Haixi Pharma (HKEX: 2637.HK) has been officially admitted to the Stock Connect list. This achievement attests to the Company’s profound industry accumulation

More